IBDEI0LT ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10343,1,3,0)
 ;;=3^Glaucoma,Moderate Stage
 ;;^UTILITY(U,$J,358.3,10343,1,4,0)
 ;;=4^365.72
 ;;^UTILITY(U,$J,358.3,10343,2)
 ;;=^340514
 ;;^UTILITY(U,$J,358.3,10344,0)
 ;;=365.73^^44^563^30
 ;;^UTILITY(U,$J,358.3,10344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10344,1,3,0)
 ;;=3^Glaucoma,Severe Stage
 ;;^UTILITY(U,$J,358.3,10344,1,4,0)
 ;;=4^365.73
 ;;^UTILITY(U,$J,358.3,10344,2)
 ;;=^340515
 ;;^UTILITY(U,$J,358.3,10345,0)
 ;;=365.74^^44^563^14
 ;;^UTILITY(U,$J,358.3,10345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10345,1,3,0)
 ;;=3^Glaucoma,Indeterm Stage
 ;;^UTILITY(U,$J,358.3,10345,1,4,0)
 ;;=4^365.74
 ;;^UTILITY(U,$J,358.3,10345,2)
 ;;=^340516
 ;;^UTILITY(U,$J,358.3,10346,0)
 ;;=V19.11^^44^563^5
 ;;^UTILITY(U,$J,358.3,10346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10346,1,3,0)
 ;;=3^Family Hx Glaucoma
 ;;^UTILITY(U,$J,358.3,10346,1,4,0)
 ;;=4^V19.11
 ;;^UTILITY(U,$J,358.3,10346,2)
 ;;=^340617
 ;;^UTILITY(U,$J,358.3,10347,0)
 ;;=V19.19^^44^563^6
 ;;^UTILITY(U,$J,358.3,10347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10347,1,3,0)
 ;;=3^Family Hx Oth Spec Eye Disord
 ;;^UTILITY(U,$J,358.3,10347,1,4,0)
 ;;=4^V19.19
 ;;^UTILITY(U,$J,358.3,10347,2)
 ;;=^340618
 ;;^UTILITY(U,$J,358.3,10348,0)
 ;;=365.62^^44^563^8
 ;;^UTILITY(U,$J,358.3,10348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10348,1,3,0)
 ;;=3^Glauc Assoc w/ Ocular Inflamm
 ;;^UTILITY(U,$J,358.3,10348,1,4,0)
 ;;=4^365.62
 ;;^UTILITY(U,$J,358.3,10348,2)
 ;;=^268777
 ;;^UTILITY(U,$J,358.3,10349,0)
 ;;=365.00^^44^563^33
 ;;^UTILITY(U,$J,358.3,10349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10349,1,3,0)
 ;;=3^Glaucoma,Suspects
 ;;^UTILITY(U,$J,358.3,10349,1,4,0)
 ;;=4^365.00
 ;;^UTILITY(U,$J,358.3,10349,2)
 ;;=^97584
 ;;^UTILITY(U,$J,358.3,10350,0)
 ;;=365.60^^44^563^10
 ;;^UTILITY(U,$J,358.3,10350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10350,1,3,0)
 ;;=3^Glauc w/ Unspec Ocular D/O
 ;;^UTILITY(U,$J,358.3,10350,1,4,0)
 ;;=4^365.60
 ;;^UTILITY(U,$J,358.3,10350,2)
 ;;=^268775
 ;;^UTILITY(U,$J,358.3,10351,0)
 ;;=365.9^^44^563^35
 ;;^UTILITY(U,$J,358.3,10351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10351,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,10351,1,4,0)
 ;;=4^365.9
 ;;^UTILITY(U,$J,358.3,10351,2)
 ;;=^51160
 ;;^UTILITY(U,$J,358.3,10352,0)
 ;;=365.22^^44^563^12
 ;;^UTILITY(U,$J,358.3,10352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10352,1,3,0)
 ;;=3^Glaucoma,Acute Angle Closure
 ;;^UTILITY(U,$J,358.3,10352,1,4,0)
 ;;=4^365.22
 ;;^UTILITY(U,$J,358.3,10352,2)
 ;;=^268754
 ;;^UTILITY(U,$J,358.3,10353,0)
 ;;=365.59^^44^563^7
 ;;^UTILITY(U,$J,358.3,10353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10353,1,3,0)
 ;;=3^Glauc Assoc w/ Lens D/O
 ;;^UTILITY(U,$J,358.3,10353,1,4,0)
 ;;=4^365.59
 ;;^UTILITY(U,$J,358.3,10353,2)
 ;;=^268773
 ;;^UTILITY(U,$J,358.3,10354,0)
 ;;=365.44^^44^563^9
 ;;^UTILITY(U,$J,358.3,10354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10354,1,3,0)
 ;;=3^Glauc Assoc w/ Systemic Syndromes
 ;;^UTILITY(U,$J,358.3,10354,1,4,0)
 ;;=4^365.44
 ;;^UTILITY(U,$J,358.3,10354,2)
 ;;=^268769
 ;;^UTILITY(U,$J,358.3,10355,0)
 ;;=377.14^^44^563^36
 ;;^UTILITY(U,$J,358.3,10355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10355,1,3,0)
 ;;=3^Glaucomatous Atrophy
 ;;^UTILITY(U,$J,358.3,10355,1,4,0)
 ;;=4^377.14
 ;;^UTILITY(U,$J,358.3,10355,2)
 ;;=^269218
 ;;^UTILITY(U,$J,358.3,10356,0)
 ;;=365.14^^44^563^15
 ;;^UTILITY(U,$J,358.3,10356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10356,1,3,0)
 ;;=3^Glaucoma,Infantile/Juv
 ;;^UTILITY(U,$J,358.3,10356,1,4,0)
 ;;=4^365.14
 ;;^UTILITY(U,$J,358.3,10356,2)
 ;;=^268750
 ;;
 ;;$END ROU IBDEI0LT
